Acceder Registro /

Isabel Legaz Pérez

Buscador

Collados-Ros A, Muro M, Legaz I. Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review. Biomedicines. 2024 Jan 17;12(1):208. doi: 10.3390/biomedicines12010208. PubMed PMID: 38255313.
AÑO: 2024; IF: 4.7
Legaz I, Navarro-Noguera E, Collados-Ros A, Bolarin JM, Muro M. Biomarkers of Innate Immunity and Immunological Susceptibility to Viral Infection in Patients with Alcoholic Cirrhosis. Biomedicines. 2024 Feb 1;12(2):336. doi: 10.3390/biomedicines12020336. PubMed PMID: 38397937; PubMed Central PMCID: PMC10887413.
AÑO: 2024; IF: 4.7
Legaz I, Jimenez-Coll V, Gonzalez-Lopez R, Fernandez-Gonzalez M, Alegria-Marcos MJ, Galian JA, Botella C, Moya-Quiles R, Muro-Perez M, Minguela A, Llorente S, Muro M. MicroRNAs as Potential Graft Rejection or Tolerance Biomarkers and Their Dilemma in Clinical Routines Behaving like Devilish, Angelic, or Frightening Elements. Biomedicines. 2024 Jan 5;12(1):116. doi: 10.3390/biomedicines12010116. PubMed PMID: 38255221.
AÑO: 2024; IF: 4.7
Legaz I, Muro M. Natural Killer Cells and Their Implications in Immune Response Diversification in Clinical Pathology and Neoplastic Processes. Int J Mol Sci. 2023 Apr 24;24(9):7743. doi: 10.3390/ijms24097743. PubMed PMID: 37175450; PubMed Central PMCID: PMC10178591.
AÑO: 2023; IF: 5.6
Boix F, Jimenez-Coll V, Legaz I, Alfaro R, Moya-Quiles MR, Pena-Moral J, Minguela A, Llorente S, Muro M. Higher Expression of Activated CD8+ T Lymphocytes (CD8+CD25+, CD8+CD69+ and CD8+CD95+) Mediate Early Post-Transplant Acute Tubular Injury in Kidney Recipients. Front Biosci (Landmark Ed). 2023 Jun 27;28(6):119. doi: 10.31083/j.fbl2806119. PubMed PMID: 37395036.
AÑO: 2023; IF: 3.1

Instituto de Investigación Sanitaria Acreditado

ISCII

Fondo Social Europeo "El FSE Invierte en tu futuro"

Fondo Social Europeo

Sello de Calidad Europeo "HR Excellence in Research"

HRS4R